Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

BEAT AF

Financiado

Cerrado

Ground BrEAking Electroporation based inTervention for Atrial Fibrillation treat...

Ground BrEAking Electroporation based inTervention for Atrial Fibrillation treatment BEAT AF Atrial fibrillation (AF), the most common arrhythmia, accounts for 1/3rd of Cardiovascular expenses, with over 10 millions affected in Europe. In addition to significant impact on quality of life, AF exposes patients to stroke, he... ver más

28/02/2026

UBx

7M€

Presupuesto del proyecto: 7M€

Líder del proyecto

UNIVERSITE DE BORDEAUX No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 10 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2021-01-18

SC1-BHC-08-2020: New interventions for Non-Communica...

I+D

Cerrada hace 5 años

0% 88% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

10 Participantes

UBx

1.47M€ | Lider

MEDICAL UNIVERSITY OF GRAZ

263.88K€ | Participante

EIT Urban Mobility Innovatio...

245.75K€ | Participante

FARAPULSE INC

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

RTC-2016-5445-1 ABLAVIEW - Un Sistema Innovador de Ablación por Radio-Frecue... 584K€ Cerrado

ABLAVIEW An Innovative Image Guided Radiofrequency Ablation System to... 4M€ Cerrado

DIN2019-010831 Mapeo cardiaco electrofisiológico para predecir la eficacia... 70K€ Cerrado

MRI + ABLATION Magnetic Resonance Guidance of Catheter Based Ablation for C... 150K€ Cerrado

DRAIOCHT DRAIOCHT A low cost minimally invasive platform medical dev... 130K€ Cerrado

HIFUSWI-INTRACARDIAC High intensity focused ultrasound intracardiac ablation with... 194K€ Cerrado

Duración del proyecto: 61 meses Fecha Inicio: 2021-01-18
Fecha Fin: 2026-02-28

Líder del proyecto

UNIVERSITE DE BORDEAUX No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 7M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Atrial fibrillation (AF), the most common arrhythmia, accounts for 1/3rd of Cardiovascular expenses, with over 10 millions affected in Europe. In addition to significant impact on quality of life, AF exposes patients to stroke, heart failure, dementia and death. AF is the most commonly ablated arrhythmia. The Pulmonary Vein Isolation (PVI) is the cornerstone of AF ablation, preventing recurrences, especially in patients with paroxysmal AF. Catheter ablation of AF uses either radio-frequency (RF) or cryothermal (cryo) energy. Common to these thermal energy sources is their reliance on time-dependent conductive heating/cooling and the fact that these modalities ablate all tissue types indiscriminately. The ablation procedure remains long, requires skills and expertise, and has a limited success rate, mostly because of non-durable lesions after PVI implying frequent redo procedures. And these energies are associated with rare but severe complications due to their thermal nature. The goal of BEAT AF is to disrupt AF ablation by achieving durable PVI with permanent, coalescent and transmural ablation lesions using Pulsed Electric Field (PEF) energy. PEF is non-thermal and creates nanoscale pores in cell membranes. Cardiac cells are highly sensitive to PEF unlike phrenic and oesophageal cells. BEAT AF aims to demonstrate that PEF ablation is faster, more effective and safer (tissue selectivity) than RF or cryo ablation. For this purpose, two distinct randomized clinical trials will be conducted: 1) to provide first comparative evidence of the superiority of PEF over RF on the rate of 1-year recurrence for paroxysmal AF, and 2) to provide first evidence of potential efficacy of PEF on the rate of 1-year clinical recurrence for persistent AF. The BEAT AF consortium gathers 9 European renowned clinical centres (France, Czech Republic, Germany, Austria, Belgium) to set the ground for large trials and contribute to decrease the huge burden of AF in Europe.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores